A national cross-sectional study among drug-users in France: epidemiology of HCV and highlight on practical and statistical aspects of the design

被引:56
作者
Jauffret-Roustide, Marie [1 ,2 ]
Le Strat, Yann [1 ]
Couturier, Elisabeth [1 ]
Thierry, Damien [3 ,4 ]
Rondy, Marc [2 ]
Quaglia, Martine [5 ]
Razafandratsima, Nicolas [5 ]
Emmanuelli, Julien [1 ]
Guibert, Gaelle [2 ]
Barin, Francis [3 ,4 ]
Desenclos, Jean-Claude [1 ]
机构
[1] Natl Inst Publ Hlth Surveillance, Dept Infect Dis, St Maurice, France
[2] Univ Paris 05, INSERM, UMR CNRS 8136, Ctr Res Psychotrop Hlth Mental Hlth & Soc,U611, Paris, France
[3] Univ Tours, INSERM, ERI 19, Tours, France
[4] CHU Bretonneau, Natl Reference Ctr HIV, F-37044 Tours, France
[5] Natl Inst Demog Studies, Paris, France
关键词
HEPATITIS-C-VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; RISK-FACTORS; HARM-REDUCTION; HIV-INFECTION; SUBSTANCE USE; B-VIRUS; INJECTION; PREVALENCE; COHORT;
D O I
10.1186/1471-2334-9-113
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Epidemiology of HCV infection among drug users (DUs) has been widely studied. Prevalence and sociobehavioural data among DUs are therefore available in most countries but no study has taken into account in the sampling weights one important aspect of the way of life of DUs, namely that they can use one or more specialized services during the study period. In 2004-2005, we conducted a national seroepidemiologic survey of DUs, based on a random sampling design using the Generalised Weight Share Method (GWSM) and on blood testing. Methods: A cross-sectional multicenter survey was done among DUs having injected or snorted drugs at least once in their life. We conducted a two stage random survey of DUs selected to represent the diversity of drug use. The fact that DUs can use more than one structure during the study period has an impact on their inclusion probabilities. To calculate a correct sampling weight, we used the GWSM. A sociobehavioral questionnaire was administered by interviewers. Selected DUs were asked to self-collect a fingerprick blood sample on blotting paper. Results: Of all DUs selected, 1462 (75%) accepted to participate. HCV seroprevalence was 59.8% [95% CI: 50.7-68.3]. Of DUs under 30 years, 28% were HCV seropositive. Of HCV-infected DUs, 27% were unaware of their status. In the month prior to interview, 13% of DUs shared a syringe, 38% other injection parapharnelia and 81% shared a crack pipe. In multivariate analysis, factors independently associated with HCV seropositivity were age over 30, HIV seropositivity, having ever injected drugs, opiate substitution treatment (OST), crack use, and precarious housing. Conclusion: This is the first time that blood testing combined to GWSM is applied to a DUs population, which improve the estimate of HCV prevalence. HCV seroprevalence is high, indeed by the youngest DUs. And a large proportion of DUs are not aware of their status. Our multivariate analysis identifies risk factors such as crack consumption and unstable housing.
引用
收藏
页数:12
相关论文
共 74 条
[1]   Global estimates of prevalence of HCV infection among injecting drug users [J].
Aceijas, Carmen ;
Rhodes, Tim .
INTERNATIONAL JOURNAL OF DRUG POLICY, 2007, 18 (05) :352-358
[2]   The prevalence of hepatitis C virus infection in the United States, 1988 through 1994 [J].
Alter, MJ ;
Kruszon-Moran, D ;
Nainan, OV ;
McQuillan, GM ;
Gao, FX ;
Moyer, LA ;
Kaslow, RA ;
Margolis, HS .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (08) :556-562
[3]  
[Anonymous], 1998, MMWR-MORBID MORTAL W, V50, P1
[4]  
Ardilly P., 2001, SURV METHODOL, V27, P109
[5]   Estimating past hepatitis C infection risk from reported risk factor histories: implications for imputing age of infection and modeling fibrosis progression [J].
Bacchetti, Peter ;
Tien, Phyllis C. ;
Seaberg, Eric C. ;
O'Brien, Thomas R. ;
Augenbraun, Michael H. ;
Kral, Alex H. ;
Busch, Michael P. ;
Edlin, Brian R. .
BMC INFECTIOUS DISEASES, 2007, 7 (1)
[6]   Hepatitis C virus infection and injection drug users: Prevention, risk factors, and treatment [J].
Backmund, M ;
Reimer, J ;
Meyer, K ;
Gerlach, JT ;
Zachoval, R .
CLINICAL INFECTIOUS DISEASES, 2005, 40 :S330-S335
[7]  
BELLO PY, 2005, PHENOMENES EMERGENTS
[8]  
Coutinho RA, 1998, BRIT MED J, V317, P424, DOI 10.1136/bmj.317.7156.424
[9]   The force of numbers: why hepatitis C is spreading among Australian injecting drug users while HIV is not [J].
Crofts, N ;
Aitken, CK ;
Kaldor, JM .
MEDICAL JOURNAL OF AUSTRALIA, 1999, 170 (05) :220-221
[10]   Epidemiology of hepatitis C virus infection among injecting drug users in Australia [J].
Crofts, N ;
Jolley, D ;
Kaldor, J ;
van Beek, I ;
Wodak, A .
JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 1997, 51 (06) :692-697